| Year |
Citation |
Score |
| 2017 |
Shan L, Deng K, Gao H, Xing S, Capoferri AA, Durand CM, Rabi SA, Laird GM, Kim M, Hosmane NN, Yang HC, Zhang H, Margolick JB, Li L, Cai W, et al. Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection. Immunity. 47: 766-775.e3. PMID 29045905 DOI: 10.1016/J.Immuni.2017.09.014 |
0.804 |
|
| 2016 |
Hou Y, Xing S, Shao J, Yin Z, Hao L, Yang T, Zhang H, Zhu M, Chen H, Li X. Synthesis of seven-membered iminosugars fused thiazolidin-4-one and benzthiazinan-4-one and their HIV-RT inhibitory activity. Carbohydrate Research. PMID 27017974 DOI: 10.1016/j.carres.2016.02.011 |
0.383 |
|
| 2014 |
Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. The Journal of Antimicrobial Chemotherapy. 69: 28-33. PMID 23999005 DOI: 10.1093/Jac/Dkt338 |
0.814 |
|
| 2013 |
Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, ... ... Xing S, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. Plos Pathogens. 9: e1003834. PMID 24385908 DOI: 10.1371/Journal.Ppat.1003834 |
0.759 |
|
| 2013 |
Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discovery Today. 18: 541-51. PMID 23270785 DOI: 10.1016/J.Drudis.2012.12.008 |
0.73 |
|
| 2013 |
Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (Georgetown, Tex.). 12: 452-62. PMID 23255218 DOI: 10.4161/Cc.23309 |
0.767 |
|
| 2012 |
Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, Liu JO, Siliciano RF. Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. The Journal of Antimicrobial Chemotherapy. 67: 398-403. PMID 22160146 DOI: 10.1093/Jac/Dkr496 |
0.798 |
|
| 2011 |
Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Science Translational Medicine. 3: 91ra63. PMID 21753122 DOI: 10.1126/Scitranslmed.3002304 |
0.739 |
|
| 2011 |
Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. Journal of Virology. 85: 6060-4. PMID 21471244 DOI: 10.1128/Jvi.02033-10 |
0.823 |
|
| 2009 |
Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. The Journal of Clinical Investigation. 119: 3473-86. PMID 19805909 DOI: 10.1172/Jci39199 |
0.687 |
|
| 2007 |
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. The New England Journal of Medicine. 356: 2614-21. PMID 17582071 DOI: 10.1056/Nejmoa067710 |
0.69 |
|
| Show low-probability matches. |